Drug launches to watch in 2019

J&J needs the drug to hit the ground running because its existing prostate cancer blockbuster Zytiga is faceing generic competition in the US, which accounts for around half of the

J&J earnings top expectations, but feels the squeeze in US

Prostate cancer drug Zytiga sales fall 12.7% in the US thanks to new generic competition, while pulmonary hypertension medicine Tracleer declined by around 25% for the same reason.

J&J’s Erleada cleared for early prostate cancer in Europe

Xtandi is also approved for more advanced, metastasised CRPC, where it competes with J&J’s $4bn-plus androgen synthesis inhibitor Zytiga (abiraterone acetate), and reported $180m in alliance revenues in ... Zytiga lost a patent infringement appeal last

Generic threat looms to J&J’s blockbuster Zytiga in US

Zytiga will enter the market and will result in a significant decline in sales.”. ... J&J isn’t the only company that would be affected by an early generic Zytiga launch.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]